Blog

  • Action For Humanity statement on atrocities at aid sites in Gaza – ReliefWeb

    1. Action For Humanity statement on atrocities at aid sites in Gaza  ReliefWeb
    2. At least 58 killed as Israel intensifies offensive in Gaza  Australian Broadcasting Corporation
    3. Israel kills nearly 600 Palestinians at aid centres: All you need to know  Al Jazeera
    4. ‘It’s a Killing Field’: IDF Soldiers Ordered to Shoot Deliberately at Unarmed Gazans Waiting for Humanitarian Aid  Haaretz
    5. Israel halts aid into northern Gaza, officials say, clans deny Hamas is stealing it  Reuters

    Continue Reading

  • Gene Haas to drive one of his F1 cars at Goodwood Festival of Speed

    Gene Haas to drive one of his F1 cars at Goodwood Festival of Speed

    Haas have announced that team founder and owner Gene Haas, as well as team boss Ayao Komatsu, will get behind the wheel of Formula 1 machinery at the upcoming Goodwood Festival of Speed.

    After marking their 200th F1 start at the recent Canadian Grand Prix, the US-led operation will continue celebrations with a series of activities at the annual motorsport gathering, which features a world-famous hillclimb.

    This includes Gene Haas driving the 2023-specification VF-23 on Friday, July 11, with Komatsu also making an appearance in the following season’s VF-24.

    Haas revealed that the pair got their first taste of F1 machinery together during a private shakedown at Silverstone a couple of weeks ago, with Gene completing a handful of laps on the Stowe track configuration.

    Kazuki Nakajima, Vice Chairman of Toyota Gazoo Racing Europe, will kick off the four-day event by driving the VF-23 on Thursday, July 10, alongside Komatsu in the VF-24, before full-time Haas drivers Ollie Bearman and Esteban Ocon take over weekend driving duties.

    Alongside their hillclimb activities, Haas will have a strong presence within the Ballroom Paddock, showcasing the VF-16 – the team’s first F1 car – as well as the VF-25, which will be raced in the British Grand Prix just a few days before.

    Haas’ activities at Goodwood coincide with the Festival of Speed’s celebration to mark the 75th anniversary of the F1 World Championship – several other teams and drivers up and down the grid are also set to attend the event.

    Continue Reading

  • AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER| Amgen

    AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER| Amgen

    At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone

    THOUSAND OAKS, Calif., June 30, 2025 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis. 

    Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS as compared to placebo plus chemotherapy in people living with unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer with FGFR2b overexpression and who are non-HER2 positive. FGFR2b overexpression was defined as 2+/3+ staining in ≥10% of tumor cells by centrally performed immunohistochemistry (IHC) testing.

    Gastric cancer is the fifth leading cause of cancer-related death worldwide, with nearly one million new cases and over 650,000 deaths globally each year 1, highlighting a critical unmet medical need.

    “Most patients with gastric cancer are diagnosed at an advanced stage, with poor prognosis, low survival rates and limited therapeutic options,” said Jay Bradner, M.D., executive vice president of Research and Development at Amgen. “These first positive top-line results of an FGFR2b targeted monoclonal antibody from our Phase 3 FORTITUDE-101 study mark a meaningful advance in the development of effective targeted therapy for gastric cancer.”

    The most common treatment-emergent adverse events (>25%) in patients treated with bemarituzumab plus chemotherapy were reduced visual acuity, punctate keratitis, anaemia, neutropenia, nausea, corneal epithelium defect and dry eye. While ocular events were consistent with the Phase 2 experience and observed in both arms, they occurred with greater frequency and severity in the Phase 3 bemarituzumab arm.

    Detailed results from the trial will be shared at a future medical meeting.

    FORTITUDE-101 was conducted with the support of Zai Lab. Zai Lab holds co-development and commercialization rights for bemarituzumab for mainland China, Hong Kong, Macau, and Taiwan.

    A Phase 3 study of bemarituzumab plus chemotherapy and nivolumab is also ongoing in patients with first-line gastric cancer, with a data readout anticipated in H2 2025.

    About FGFR2b 
    The FGFR2b protein (also known as fibroblast growth factor receptor 2b) is an emerging biomarker which, when overexpressed, promotes aberrant signaling leading to tumor cell proliferation.2

    The FGFR2b protein is overexpressed by G/GEJ tumor cells in approximately 38% of patients with advanced G/GEJ cancer. FGFR2b protein overexpression is defined as 2+/3+ staining intensity on tumor cell membrane, as detected by immunohistochemistry (IHC) testing. In approximately 16% of patients with advanced G/GEJ cancer, FGFR2b protein overexpression is observed on ≥10% of tumor cells by IHC.3

    About FORTITUDE-101 
    FORTITUDE-101 is a randomized, multi-center, double-blind, placebo-controlled Phase 3 study of bemarituzumab plus mFOLFOX6 versus placebo plus mFOLFOX6 as first-line therapy in advanced G/GEJ cancer with FGFR2b overexpression. The FORTITUDE-101 trial spanned 300 sites across 37 countries, with 547 patients enrolled.

    The primary outcome measure of the trial is overall survival in patients with FGFR2b ≥10% 2+/3+ tumor cell staining.  Key secondary outcome measures include progression-free survival and overall response rate. Candidates were excluded from the trial if they were known to be human epidermal growth factor receptor 2 (HER2) positive. FORTITUDE-101 included more comprehensive ocular-related monitoring than previous studies of bemarituzumab.

    About Amgen
    Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world’s toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

    In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

    For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram,  YouTube and Threads. 

    Amgen Forward-Looking Statements

    This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast), our acquisitions of ChemoCentryx, Inc. or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon’s business, performance and opportunities, and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

    No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.

    Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions, including those resulting from geopolitical relations and government actions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our sustainability objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

    The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration, and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates.

    CONTACT: Amgen, Thousand Oaks Elissa Snook, 609-251-1407 (media)Justin Claeys, 805-313-9775 (investors) 

    REFERENCES

    1. Bray F, et al. CA Cancer J Clin. 2024;74(3);229-263
    2. Wainberg ZA, et al. Lancet Oncol. 2022;23(11):1430-40
    3. Rha SY, et al. JCO Precis Oncol. 2025; 9 (e2400710). DOI:10.1200/PO-24-00710

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-announces-positive-topline-phase-3-results-for-bemarituzumab-in-fibroblast-growth-factor-receptor-2b-fgfr2b-positive-first-line-gastric-cancer-302494006.html

    SOURCE Amgen


    Continue Reading

  • Paul Aron to drive in first practice at Silverstone as Alpine agree deal with Kick Sauber

    Paul Aron to drive in first practice at Silverstone as Alpine agree deal with Kick Sauber

    Alpine Reserve Driver Paul Aron will make his free practice debut at the upcoming British Grand Prix weekend with Kick Sauber after the rival teams came to an agreement to share his driving services.

    The Estonian 21-year-old, who competed in F2 last season, is not racing competitively this year, with his focus currently on helping Alpine with simulator work as they try and claw their way back up the standings from P10 in the Championship.

    Alpine entered the 2025 F1 season with plenty of driving talent in reserve. While Ryo Hirakawa soon departed for Haas, the Enstone-based squad still have Jack Doohan alongside Aron – the Australian had started the year in a full-time race seat but was swapped out in favour of Franco Colapinto ahead of the Emilia-Romagna Grand Prix.

    The agreement Alpine have reached with Kick Sauber will release Aron for two FP1 sessions this season, with every team having to give up four FP1 sessions across the year for a ‘Friday’ driver, unless they are running a rookie in one of their cars.

    Aron will don the black and green of Kick Sauber at Silverstone this weekend, and also at the Hungaroring later this summer. Apart from that, he remains an Alpine driver and will take part in three further FP1 sessions for the French team with dates to be confirmed in due course.

    “I am very pleased to be given the opportunity to have valuable track time in Formula 1, so thanks to BWT Alpine Formula One Team for coming to this arrangement,” Aron said.

    “It is no secret that my desire is to one day race full-time in Formula 1 so any chance to be on track in a competitive environment is an important stepping stone.

    “While I continue to focus on my development with Alpine, I do look forward to the two sessions with Kick Sauber and giving my maximum effort to them at Silverstone and Budapest.”

    Kick Sauber only need to give up two FP1 sessions this season, as they are running a designated rookie in their other car in Gabriel Bortoleto. As such, Aron will replace Nico Hulkenberg at Silverstone and in Budapest.

    “It is in our interests to maximise any driving opportunities for our young talent, so it is good to have an agreement with Sauber for Paul to drive in Free Practice 1 in Silverstone and Budapest,” added Flavio Briatore, Alpine’s Executive Advisor.

    “We are seeing varied success from last year’s Formula 2 drivers this year up and down the grid, and Paul was a front runner in that category, so this is an opportunity for him and the team to continue his progress and to give him valuable track time.”

    Aron finished third in last year’s F2 Championship, behind Bortoleto and Isack Hadjar – both of whom are impressing in their first full season as F1 drivers.

    While teams have often released drivers for these sorts of duties in the past, what makes this agreement rare is the fact that Kick Sauber and Alpine are battling each other in the Championship, Kick Sauber lying ninth in the standings just ahead of Alpine.

    Continue Reading

  • Uncertainty clouds fragile Israel-Iran ceasefire one week in

    Uncertainty clouds fragile Israel-Iran ceasefire one week in





    Uncertainty clouds fragile Israel-Iran ceasefire one week in – Daily Times


































    Continue Reading

  • ‘Dukes of Hazzard’ stunt car jump in Kentucky

    ‘Dukes of Hazzard’ stunt car jump in Kentucky

    A stuntman drove a replica of the “Dukes of Hazzard” General Lee car over a fountain in Somerset, Kentucky, over the weekend, in a feat inspired by the series.

    The stunt took place at the Somernites Cruise, a classic car event, in downtown Somerset on Saturday, June 28. According to local outlets the Lexington Herald Leader and the Commonwealth Journal, 35,000 people were in attendance to watch stunt jumper Raymond Kohn complete his 30th “Dukes of Hazzard” jump over a fountain in the city’s square.

    “It was so popular the first time, people asked me to come back and it became more popular – and I became the go-to-guy to jump the General Lee,” Kohn told the Herald Leader. Kohn later told the outlet he had recently undergone surgery to remove a brain tumor, adding he asked the surgeon, “Will I be able to jump after the surgery?”

    “Dukes” stars John Schneider, who played Bo Duke, and Byron Cherry, who played Coy Duke, were also in attendance at the event.

    “The Dukes of Hazzard,” which ran for 146 episodes across seven seasons, followed the “good ol’” Duke boys of rural Hazzard County, Georgia. Not without its controversies, reruns of the show are few and far between due to its Confederate flag imagery. TV Land dumped the show several years ago, and Warner Bros., which produced the series, halted production of toy replicas of the General Lee, an orange 1969 Dodge Charger stock car driven by rambunctious Southern cousins Luke and Bo. The car famously features an image of the Confederate flag on its roof.

    Continue Reading

  • Linear structure gives dysprosium complex record-breaking magnetic properties | Research

    Linear structure gives dysprosium complex record-breaking magnetic properties | Research

    A new dysprosium complex retains magnetic memory at 100K, the highest temperature recorded for this class of compound. The researchers behind the work attribute the material’s properties to its unusual linear structure, and suggest that such complexes could drastically reduce the space required to store large amounts of information in modern data centres.

    Single-molecule magnets can reduce the physical size of storage systems by increasing data density. But once they have been magnetised by an external magnetic field, these compounds generally need to be kept under extremely cold temperatures to prevent magnetic memory loss, limiting their everyday potential. One factor that has capped these compounds’ working temperatures to around 80K is the bent arrangement of bonds around their dysprosium atoms, which aids magnetic relaxation and loss of information.

    A crystal structure of the dysprosium complex

    Now, researchers at the University of Manchester in the UK have synthesised a dysprosium complex in which the bonding around the central dysprosium atom takes on a more linear structure. An alkene incorporated into the ligand backbone helps pull the two dysprosium–nitrogen bonds into a straighter arrangement. This configuration increases the portion of angular momentum aligning with the principal axis, elevating overall magnetism of the compound. The linear motif also helps to slow magnetic relaxation, allowing the compound to remain magnetised up to 100K.

    The researchers point out that because the magnet works at temperatures above that of liquid nitrogen (77K), its use could now be feasible in large data centres. The team now plans hopes to find even better single-molecule magnets by exploring complexes with even wider angles and more charge dense ligands.

    Continue Reading

  • Bonzi stuns Medvedev at Wimbledon – ATP Tour

    1. Bonzi stuns Medvedev at Wimbledon  ATP Tour
    2. Wimbledon Day 1 Men’s Predictions Including Daniil Medvedev vs Benjamin Bonzi  Last Word On Sports
    3. Britain Wimbledon Tennis  WV News
    4. Wimbledon LIVE: Svitolina through as Jabeur pulls out, Medvedev in action on men’s side  Flashscore.com
    5. Benjamin Bonzi vs. Daniil Medvedev Prediction, Odds, Picks for Wimbledon 2025  dimers.com

    Continue Reading

  • Hubble Spots Reflection Nebula in Taurus Molecular Cloud

    Hubble Spots Reflection Nebula in Taurus Molecular Cloud

    Astronomers using the NASA/ESA Hubble Space Telescope have produced an outstanding image of the reflection nebula GN 04.32.8.

    This Hubble image shows GN 04.32.8, a reflection nebula some 480 light-years away in the constellation of Taurus. The color composite was assembled from images taken in visible and near-infrared light. It is based on data obtained through two filters. The color results from assigning different hues to each monochromatic image associated with an individual filter. Image credit: NASA / ESA / Hubble / G. Duchêne.

    GN 04.32.8 is located approximately 480 light-years away in the constellation of Taurus.

    Also known as DG 41, it is a small part of the stellar nursery known as the Taurus Molecular Cloud.

    “Reflection nebulae are clouds of dust in space that don’t emit their own light, as other nebulae do,” the Hubble astronomers said in a statement.

    “Instead, the light from nearby stars hits and scatters off their dust, lighting them up.”

    “Because of the way the light scatters, many reflection nebulae tend to appear blue, GN 04.32.8 included.”

    GN 04.32.8 is illuminated by a system of three bright stars in the center of the Hubble image, mainly the variable star V1025 Tauri in the very center.

    “One of those stars overlaps with part of the nebula: this is another variable star that is named HP Tauri, but is classified as a T Tauri star, for its similarity to yet another variable star elsewhere in the Taurus Molecular Complex,” the astronomers said.

    “T Tauri stars are very active, chaotic stars at an early stage of their evolution, so it’s no surprise that they appear in a prolific stellar nursery like this one.”

    “The three stars are also named HP Tau, HP Tau G2 and HP Tau G3; they’re believed to be gravitationally bound to each other, forming a triple system.”

    “Eagle-eyed viewers might notice the small, squashed, orange spot, just left of center below the clouds of the nebula, that’s crossed by a dark line,” the researchers said.

    “This is a newly-formed protostar, hidden in a protoplanetary disk that obstructs some of its light.”

    “Because the disk is edge-on to us, it’s an ideal candidate for study.”

    “We are using Hubble here to examine it closely, seeking to learn about the kinds of exoplanets that might be formed in disks like it.”

    Continue Reading

  • Sabalenka cruises past Branstine on a blistering day at Wimbledon

    Sabalenka cruises past Branstine on a blistering day at Wimbledon

    WIMBLEDON — Looking a lot like the World No. 1 and the favorite here, Aryna Sabalenka eased into the second round Monday with a 6-1, 7-5 win over qualifier Carson Branstine.

    On a record hot opening day, Sabalenka was as cool as a refreshing glass of Pimm’s on No. 1 Court, winning in 73 minutes

    Sabalenka has played only two of the past four Wimbledon tournaments — but made the semifinals both times. The people paid to figure these things out have installed Sabalenka as the one to beat, ahead of Iga Swiatek, Elena Rybakina and Coco Gauff

    All three of Sabalenka’s major singles titles have come on hard courts. She came close to breaking through on clay at Roland Garros but lost to Coco Gauff in a three-set final. She’s determined to give herself another opportunity, on a surface that suits her dynamic and increasingly evolving game.

    Wimbledon: Scores | Order of play | Draw

    The first set went about the way you’d expect when the No. 1-ranked player meets a No. 194 qualifier. This was the 24-year-old Canadian’s first Grand Slam main-draw match and was seeking only her second-career win at the Hologic WTA Tour level. She was impressive in qualifying, defeating No. 1 seed Lois Boisson — a surprise semifinalist at Roland Garros — and Bianca Andreescu along the way.

    Sabalenka won six of seven games in a scant 24 minutes. Branstine’s only game came after a 120 mph ace to avoid a shutout, delighting the supportive crowd. After double-faulting on her first set point, an unreturnable serve gave her the frame.

    Branstine settled down in the second set, finding a groove in her service games. She was serving at 5-all when Sabalenka finally solved the problem. With Sabalenka moving aggressively forward, Branstine hit a forehand into the net and, suddenly, Sabalenka was serving for the match.

    The qualifier finished with seven aces, but won only 11 of her 24 second serves. Sabalenka finished with 17 winners and 18 unforced errors, while Branstine’s numbers were 17 and 26.

    Sabalenka is now 24-5 in first-round matches at the Grand Slams and hasn’t lost in that situation in five and one-half years, going 19-0. She is a perfect 10-for-10 against qualifiers in majors and has yet to lose a set.

    .

     

     

     

     

    Continue Reading